Robert J. Hariri, M.D., Ph.D.
- Adjunct Associate Professor of Pathology, Mt. Sinai School of Medicine, New York, NY
- Founder and Executive Chairman, MYOS Corporation, Cedar Knolls, NJ
- Co-Founder and Vice-Chairman, Human Longevity, Inc., San Diego, CA
- Founder and Chairman, Celgene Cellular Therapeutics, Summit, NJ
Dr. Hariri has worked for the past 20 years to transform the field of biomedicine where his discoveries and contributions to the study of stem cells and tissue engineering have sparked the development of nearly all existing stem cell therapies. He is an accomplished surgeon, biomedical scientist, and serial entrepreneur in two technology sectors, biomedicine and aerospace. He is the Chairman, Founder, and Chief Executive Officer of Celularity, Inc., one of the world’s leading human cellular therapeutics companies. Dr. Hariri was the founder and CEO of Anthrogenesis Corporation, and after its acquisition by Celgene Corporation, served as CEO of Celgene Cellular Therapeutics. Dr. Hariri also co-founded the genomic-based health intelligence company, Human Longevity, Inc. Dr. Hariri pioneered the use of stem cells to treat a range of life-threatening human diseases, and continues today to make transformative contributions in the fields of immuno-oncology and cell therapeutics along with tissue engineering and functional regeneration. He is widely acknowledged for his discovery of pluripotent stem cells derived from the human placenta, and as a member of the team that discovered the physiological activities of tumor necrosis factor (TNF). He holds over 150 issued and pending patents for discoveries including placenta-derived stem cells, which Nature recognized as one of the ten most important patent estates in the field. He has authored over 150 published chapters, articles, and abstracts.